Brief: Hansa Biopharma Submits BLA To FDA For Imlifidase In Desensitization For Kidney Transplantation
19/12/2025 19:36
Dec 19 (Reuters) - Hansa Biopharma AB HNSA.ST: HANSA BIOPHARMA SUBMITS BLA TO FDA FOR IMLIFIDASE IN DESENSITIZATION FOR KIDNEY TRANSPLANTATION HANSA BIOPHARMA AB - FDA HAS GRANTED HANSA BIOPHARMA FAST TRACK AND ORPHAN DRUG DESIGNATION AND HANSA HAS REQUESTED PRIORITY REVIEW HANSA BIOPHARMA AB - PRIORITY REVIEW REQUESTED, POTENTIAL APPROVAL BY Q3 2026 Source text: ID:nWkr3Myh6B Further company coverage: HNSA.ST ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS